• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Macular Degeneration  • Women's Health  • Menopause  • Articles for Residents  • Alert me on articles by topic  Social Bookmarking   What's this?

Diane Feskanich, ScD; Eunyoung Cho, ScD; Debra A. Schaumberg, ScD, OD, MPH; Graham A. Colditz, MD, DrPH; Susan E. Hankinson, ScD

Arch Ophthalmol. 2008;126(4):519-524.

Objective  To investigate whether estrogen exposures are associated with lower risks of age-related macular degeneration (AMD).

Methods  Postmenopausal hormone (PMH) use, past use of oral contraceptives (OCs), ages at menarche and menopause, and parity were assessed among 74 996 postmenopausal women. Over 22 years, cases of early (n = 554) and neovascular (n = 334) AMD with a visual acuity of 20/30 or worse were identified. Cox models were used to calculate the relative risk for each exposure, adjusted for smoking and other factors.

Results  Current PMH users had a notable 48% lower risk of neovascular AMD compared with those who had never used PMH, although risk did not decline linearly with longer durations of use. Risk was lowest for PMH users who had used OCs in the past (P value for interaction, .03). In contrast, risk of early AMD was a notable 34% higher among current PMH users and OC use was unassociated with risk. The only remarkable finding for the endogenous estrogenic factors was a 26% lower risk of early AMD for parous women.

Conclusions  Although PMH and OC use were associated with a lower risk of neovascular AMD, no benefit was observed for early AMD. Factors influencing lifetime exposure to estrogens were not consistently associated with the disease.

Author Affiliations: Channing Laboratory, Department of Medicine (Drs Feskanich, Cho, Colditz, and Hankinson) and Division of Preventive Medicine (Dr Schaumberg), Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Department of Ophthalmology, Schepens Eye Research Institute, Harvard Medical School, Boston (Dr Schaumberg); and Department of Epidemiology, Harvard School of Public Health, Boston (Drs Colditz and Hankinson).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

GTx-822, an ER{beta}-Selective Agonist, Protects Retinal Pigment Epithelium (ARPE-19) from Oxidative Stress by Activating MAPK and PI3-K Pathways
Giddabasappa et al.
IOVS 2010;51:5934-5942.
ABSTRACT | FULL TEXT  

17-{beta} Estradiol Protects ARPE-19 Cells from Oxidative Stress through Estrogen Receptor-{beta}
Giddabasappa et al.
IOVS 2010;51:5278-5287.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen et al.
J. Clin. Endocrinol. Metab. 2010;95:s1-s66.
ABSTRACT | FULL TEXT  

Inverse Association of Female Hormone Replacement Therapy with Age-Related Macular Degeneration and Interactions with ARMS2 Polymorphisms
Edwards et al.
IOVS 2010;51:1873-1879.
ABSTRACT | FULL TEXT